Case report: intraductal tubulopapillary neoplasm of the pancreas with unique clear cell phenotype by Maria Ahls et al.
Ahls et al. Diagnostic Pathology 2014, 9:11
http://www.diagnosticpathology.org/content/9/1/11CASE REPORT Open AccessCase report: intraductal tubulopapillary neoplasm
of the pancreas with unique clear cell phenotype
Maria Gabriele Ahls1, Marco Niedergethmann2, Dietmar Dinter3, Christian Sauer1, Jutta Lüttges4, Stefan Post2,
Alexander Marx1 and Timo Gaiser1*Abstract: Intraductal tubulopapillary neoplasms of the pancreas are very rare tumors characterized by intraductal
tubulopapillary growth, ductal differentiation, scant intracellular mucin production and cellular dysplasia. Here, we
report the first case of an intraductal tubulopapillary neoplasm of the pancreas with clear cell morphology. The
tumor was detected during the diagnostic work-up of acute pancreatitis in a 43- year old female. Histological
examination revealed a tumor with the typical architecture of an intraductal tubulopapillary neoplasm of the
pancreas with tumor cells showing abundant clear cytoplasm and Di-PAS negativity. Immunohistochemistry
revealed positivity for Pan-CK, CK7, CK8/18, MUC1, MUC6, carbonic anhydrase IX, CD10, EMA, β-catenin and
e-cadherin. Sanger sequencing did not detect mutations for β-catenin, BRAF, KRAS, PIK3CA and GNAS. Altogether,
histology, immunohistochemical expression profile (MUC1+, MUC6+, MUC2-, MUC5AC-, thrypsin-, chymotrypsin-,
CDX2-) and sequencing results led to the diagnosis of intraductal tubulopapillary neoplasm. However, the neoplasm
consisted of cells showing abundant clear cytoplasm, a morphological pattern not being described so far in the
current classification of pancreatic intraductal neoplasms. Potential differential diagnosis and the molecular basis of
clear cell morphology are discussed. In conclusion, we consider this tumor as intraductal tubulopapillary neoplasm
of the pancreas with unique clear cell phenotype. After surgery and without adjuvant therapy, the patient’s clinical
course has been uneventful for over two years now.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1051828790117127
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The term “Intraductal tubulopapillary neoplasm (ITPN)”
was introduced by Yamaguchi and colleagues in 2009.
With less than 0.9% of all pancreatic exocrine neo-
plasms, ITPN is a rarity within pancreatic tumors [1].
About 50% of ITPNs occur in the head, 35% grow dif-
fusely and 15% are located in the tail of the pancreas.
ITPN has been included into the WHO classification of
2010 and belongs to the group of intraductal neoplasms
of the pancreas [2]. Macroscopically, ITPN presents as a
solid often obliterating intraductal mass with no visible
secreted mucin. Microscopically, the tumor shows tubu-
lopapillary growth with scanty cytoplasmic mucin, often
combined with areas of necrosis [1]. The neoplastic cells,* Correspondence: timo.gaiser@umm.de
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stated.cuboidal to columnar with enlarged nuclei, show features
of high grade dysplasia and a variable mitotic index.
Invasive carcinoma is present in up to 40% [1,2]. Immuno-
histochemically ITPN demonstrates positivity for CK7,
CK19, MUC1, MUC6 and SMAD4 while trypsin, MUC2,
MUC5AC, fascin, p53 and β-catenin are negative. Molecu-
lar analyses reveal mutations for PIK3CA in one third of
ITPNs but in contrast, mutations in KRAS and BRAF are
not detectable [1,3]. So far all reports of ITPN describe the
cytoplasm of the ITPN cells as eosinophilic to amphophi-
lic. To the best of our knowledge, this is the first report of
ITPN with clear cell morphology.Case presentation
A 43-year old female visited the outpatient clinic of the
University Medical Center Mannheim with epigastric
pain for approximately 5 days prior to presentation.
Medical history revealed no alcohol abuse or gallstone. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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(1572 U/l; normal level (nl) 73–393 U/l), alpha-amylase
(171 U/l; nl 25–115 U/l) and c-reactive protein (41.9 mg/l;
nl 0–5 mg/l). Based on the clinical findings, diagnosis of
acute pancreatitis of unknown etiology was rendered. A
subsequent MRI scan revealed dilatation of the main pan-
creatic duct with a minor contrast enhancing intraductal
tumor of approximately 3.0 cm. The tumor was partially
duct-obstructing and suggestive for the diagnosis of intra-
ductal neoplasms of the pancreas (Figure 1). The case was
discussed in a multi-disciplinary tumor board and surgical
resection was recommended. Consequently, a pylorus-
preserving pancreatoduodenectomy was performed. The
postoperative course has been uneventful for over two
years now.
Materials and methods
Histology and immunohistochemical analyses
Formalin-fixed, paraffin-embedded tissue was cut in 3 μm
sections and stained with hematoxylin and eosin for light
microscopy. A PAS, Di-PAS and Alcian blue staining
according to standard protocols for detection of mucin
was performed. Tissue sections were stained with the fol-
lowing primary antibodies, which are listed in Table 1.
Antibody binding was visualized using the Envision™ Sys-
tem as described by the manufacturer (Dako Cytomation).
Sequencing for β-catenin, BRAF, KRAS, PIK3CA and GNAS
Genomic DNA was extracted from FFPE tumor tissue
after manual macrodissection using the QIAamp DNAFigure 1 Radiological imaging. (A) Magnetic resonance cholangiopancre
fat saturated images after application of contrast media in axial and corona
(arrow) within the main duct of the pancreas head with increased signal in
pancreatic tissue (asterisks) with minor contrast media enhancement (arrowMicro kit (Qiagen, Hilden, Germany) according to the
manufacturer’s recommendations. The following PCR
primers were used for amplification of β-catenin
(exon 3), BRAF (exon 15), KRAS (exon 2), PIK3CA

















Thermal cycling conditions were 5 min at 94°C,
followed by 35 cycles of 94°C for 30 seconds, 55°C
(β-catenin, GNAS), 53°C (BRAF), 60°C (KRAS) or 58°C
(PIK3CA) for 30 seconds and 72°C for 30 seconds
followed by a final incubation at 72°C for 7 minutes. The
PCR products were ethanol precipitated, washed and
subjected to bidirectional dye-terminator sequencing
using the PCR amplification primers. After repeated
ethanol precipitation of dye labeled DNA fragments,aticography, (B) T2 weighted coronal image, (C) and (D) T1 weighted
l direction. Images showing an approximately 3.0 cm measuring tumor
tensity in the T2 weighted sequence compared to the normal
heads).
Table 1 Differential immunolabeling of intraductal neoplasms of the pancreas
IHC Mucin 1 Mucin 2 Mucin 5 AC Mucin 6 CDX 2
Subgroup
Gastric IPMN — — ++ — —
Intestinal IPMN — ++ ++ — ++
Pancreatobiliary IPMN ++ — ++ + —
Oncocytic IPMN + — + ++ —
ITPN + — — ++ —
Clear cell type ITPN (our case) Positive Negative Negative Positive Negative
Staining intensity and number of stained cells: — negative; + partially positive; ++ generally positive.
Abbreviation: IHC immunohistochemistry, IPMN intraductal papillary mucinous neoplasm, ITPN intraductal tubulopapillary neoplasm.
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Analyzer (Applied Biosystems, Foster City, CA) were
performed. Sequence electropherograms were analyzed
by Sequence Analysis 5.2 software (Applied Biosystems),
followed by manual alignment to the GenBank® refer-
ence sequences (β-catenin: X87838, BRAF: M95712,
KRAS: BC010502, PIK3CA: U79143 and GNAS: X56009.
Results
Surgical resection specimen consisted of a 8.0 × 3.5 ×
2.5 cm pancreas head with a 17.0 × 3.0 cm duodenum seg-
ment. Macroscopical examination showed an intraductal,
multilocular cystic tumor with a diameter of 2.6 cm in the
pancreatic head (distance to the ampulla 4.0 cm) occlud-
ing 90% of the lumen of the main duct consecutively
leading to a prestenotic dilatation. Histologically, the neo-
plasm appeared homogenous (“de novo-like appearance”)
with tubulopapillary glands lined by pseudostratified cells
showing abundant clear cytoplasm (Figure 2A, B). No evi-
dence for tumor invasion was detectable. The epithelial
cells lacked polarity and the majority did not adhere to the
basal membrane due to multilayering of tumor cells. The
tumor cell nuclei were enlarged, hyperchromatic and pleo-
morphic. Mitotic figures were scarce (approx. 1 per 10
high-power fields). Only a few mucin droplets in the
cytoplasm of the clear cells were detectable with histo-
chemistry; Di-PAS and alcian blue (Figure 2C, D). No
metastases were detected in eight examined lymph
nodes from the hepatic artery region. The pancreatic
tissue surrounding the tumor showed signs of chronic,
fibrotic obstructive pancreatitis with atrophy of the exo-
crine parenchyma.
Immunohistochemical staining revealed positivity of
the tumor cells for Pan-CK, CK7, CK8/18 (Figure 2E),
MUC1, MUC6 (Figure 2F), CD10 (Figure 2G), carbonic
anhydrase IX (Figure 2H) and EMA. CD10 staining
was expressed only focally and with faint intensity
(Figure 2G). E-cadherin and β-catenin showed exclusively
a membranous staining. MUC2, MUC5AC, vimentin,
chromogranin A, synaptophysin, CEA, Hep Par1, neurone
specific enolase, GLUT1, CK5/6, HMB45, CD56, estrogen-receptor, progesteron-receptor, RCC, inhibin, FLT 4, CDX
2, cyclin D1, trypsin and chymotrypsin were not detectable.
A few tumor cell nuclei were faintly stained for p53, but
not indicative for a p53 mutation. Ki67 proliferation index
reached focally 10-15%. DNA sequencing demonstrated
wild type sequences for β-catenin, BRAF, PIK3CA, GNAS
and the KRAS gene. Based on the above findings and in co-
operation with two reference pathologists for pancreas
neoplasms, the diagnosis of “ITPN with clear cell morph-
ology” was established.
Discussion and conclusions
So far 24 cases of ITPN arising in the pancreas and 13
cases arising in the bile duct have been reported
[1,4-12]. All these cases showed the characteristic ITPN
morphology with tubulopapillary growth pattern, ab-
sence of acinar differentiation and no detectable secreted
mucin. All these features were also detectable in the case
presented here but unlike the other ITPN cases, this
tumor here consisted of tumor cells with abundant clear
cytoplasm that has to the best of our knowledge, not
been reported in the literature so far. Intraductal
papillary mucinous neoplasm (IPMN), pancreatic intrae-
pithelial neoplasia (PanIN), mucinous cystic neoplasm of
the pancreas (MCN), acinar cell carcinoma, solid-
pseudopapillary neoplasm (SPN) and tumor metastasis
of renal cell carcinoma (RCC) were considered as pos-
sible differential diagnosis. In our eyes the most difficult
discrimination lies between ITPN and IPMN pancreato-
biliary type (PB type) [1,13,14]. However, MUC5AC ex-
pression, which was not detectable in our case, is
considered to be a hallmark for IPMN (Table 1) [2]. Mu-
tational analyses in IPMNs and intraductal carcinoma
revealed also a very high frequency (up to 80%) of KRAS
and GNAS (up to 60%) mutations [1,2,5]. Since in our
tumor we detected wild-type sequences for KRAS,
GNAS, β-catenin, BRAF this favors ITPN [5].
Acinar cell carcinoma, also a potential differential
diagnosis, was not considered since neither did the
tumor cells stain with PAS nor were immunohistochem-
ical markers of pancreatic exocrine enzymes like trypsin
Figure 2 Histological features and immunophenotype of the “ITPN clear cell type”. (A) A tubulopapillary tumor within the pancreatic
duct lined by pseudostratified cells showing abundant clear cytoplasm (x4), (B) higher magnification (x20), (C) Di-PAS (x20) and (D) Alcian Blue
detected only a few mucin droplets in the cytoplasm of the clear cells (x20), (E) focally positive immunohistochemical stainings for CK8/18 (x10),
(F) strong, membranous emphasised expression of MUC6 (x20), (G) focally and faint expression of CD10 (x20), (H) strong Carbonic Anhydrase IX
expression (x10).
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garded due to the size of the lesion and the lack of small
epithelial papillae [15]. In SPN a combination of solid and
pseudopapillary growth pattern is frequently present but
these tumors are usually immunoreactive for CD10,
vimentin, chromogranin A and nuclear β-catenin [16,17].Although a clear cell variant and a chromogranin A nega-
tive SPN has already been reported, our case did not show
nuclear β-catenin nor vimentin expression, therefore
ruling out SPN [16,18]. MCN is not connected to the
pancreatic duct system and contains epithelium (in rare
cases squamous epithelium), surrounded by an ovarian-
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inhibin, CEA, and chromogranin A [19]. Moreover, the
epithelial component of MCN is positive for MUC5AC
and negative for MUC1 and MUC2, obviously in differ-
ence to our results [2,20]. Metastasis of an extrapancreatic
primary clear cell tumor, particularly renal RCC was ser-
iously considered especially since CD10 expression was
expressed focally and with faint intensity, however no in-
vasiveness and the absence of vimentin positivity argues
against pancreatic metastases of RCC. In addition, the pro-
file of expressed mucins, several tumor free MRI scans of
the kidneys and the uneventful clinical follow-up for now
over two years rule out RCC metastases [21].
The molecular basis of clear cell morphology in the
presented tumor is unknown and only a few studies dis-
cussed genesis of clear cell morphology. So far, the best
studied tumor in this context is clear cell RCC and hyp-
oxia regulatory factors have been identified as driving
force for the clear cell phenotype [22]. HIF-1α, carbonic
anhydrase IX, and GLUT1 have been described as
markers for the hypoxia-inducible factor pathway [23].
In the current case we were able to detect a strong stain-
ing against carbonic anhydrase IX (FLT4 or GLUT1
were negative) arguing that the clear cell phenomenon
in our case might also be associated with hypoxia. How-
ever, we cannot rule out that carbonic anhydrase IX,
which can also been seen in normal stomach, liver
and gallbladder may simply represent a differentiation
towards the pyloropancreatic pathway of intraductal
papillary neoplasms. Basturk and colleagues claimed that
the tubular/tubulopapillary pathway of ITPN forms a
subgroup within the pyloropancreatic pathway [24].
In conclusion, we consider this tumor as ITPN with
very unusual clear cell morphology. Recognition of simi-
lar tumor cases and clinico-pathological correlations are
needed to illuminate the clinical relevance of this obvi-
ously rare ITPN subgroup.
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